Philips and B. Braun launch Onvision needle tip tracking, a breakthrough in real-time ultrasound guidance for regional anesth...
10 Septiembre 2019 - 3:00AM
Philips and B. Braun launch Onvision needle tip tracking, a
breakthrough in real-time ultrasound guidance for regional
anesthesia
September 10, 2019
- Integrated point-of-care solution empowers anesthesiologists to
perform regional anesthesia procedures, such as peripheral nerve
blocks, more safely and efficiently
- Regional anesthesia can have significant advantages over
general anesthesia for both patients and hospitals
- Available on the B. Braun and Philips Xperius point-of-care
ultrasound system, combining Philips’ Onvision needle tip tracking
technology and B. Braun’s Stimuplex Onvision needles
Amsterdam, the Netherlands and Melsungen, Germany
– Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in
health technology, and B. Braun Melsungen AG, a global leader in
regional anesthesia and pain management, today announced the launch
of Onvision, a breakthrough ultrasound guidance solution for
real-time needle tip tracking in regional anesthesia. Available on
the latest version of the B. Braun and Philips Xperius ultrasound
system, Onvision gives anesthesiologists the confidence to
accurately position the needle tip inside the body. The
introduction is part of a multi-year strategic alliance between
Philips and B. Braun to innovate in ultrasound-guided regional
anesthesia, a rapidly growing alternative to general anesthesia.
Onvision is being launched at the 38th Annual Conference of the
European Society of Regional Anaesthesia and Pain Therapy (ESRA) in
Bilbao, Spain (11-14 September).
Accurate needle placement is critical to the success of regional
anesthesia procedures, such as peripheral nerve blocks, both in
terms of effective pain relief and the avoidance of unintended
nerve and vessel punctures or collateral damage to surrounding
tissue. While real-time ultrasound imaging has proved to be a
valuable tool for needle guidance, failure to optimally visualize
the needle tip remains a challenge for both novice [1] and
experienced [2] anesthetists. Currently, 10-20% of all peripheral
nerve blocks are ineffective on the first attempt [3]. By
simplifying alignment between the needle and ultrasound probe,
Onvision reduces the effort needed to interpret the ultrasound
image. This allows the anesthesiologist to more confidently guide
the tip of the needle to its target.
“Regional anesthesia is a rapidly growing alternative to general
anesthesia and has the potential to improve patient outcomes as
well as increase workflow efficiency in the hospital,” said Bert
van Meurs, Chief Business Leader, Image Guided Therapy at Royal
Philips. “By combining B. Braun’s expertise in needle design with
Philips’ capabilities in real-time image guidance, we’ve created a
solution to one of the biggest challenges in regional anesthesia –
accurate positioning of the needle tip in the body. Our alliance
with B. Braun is a strong example of our commitment to partner with
industry leaders to grow our footprint in the therapy market.”
“Our customers want intuitive solutions that allow them to focus
on the patient rather than the technology, so they can achieve the
best outcomes. As demand for regional anesthesia grows, improved
efficiency can also help reduce the pressure of an increasing
workload,” said Dr. Meinrad Lugan, Member of the Board for the
Hospital Care Division at B. Braun. “Onvision is a perfect example
of what can be achieved through shared expertise to meet the
evolving needs of our customers, bringing regional anesthesia to
more patients in more hospitals worldwide.”
Together, B. Braun’s Stimuplex Onvision needles and Philips’
Onvision needle tip tracking technology indicate the position of
the needle tip in relation to the ultrasound viewing plane to an
accuracy of better than 3mm. A sensitive micro-sensor placed on the
needle, combined with advanced signal processing and visualization
techniques on the Xperius system, indicate the real-time location
of the needle tip in relation to the 2D ultrasound viewing plane.
The solution provides greater flexibility in needle trajectory and
can reduce procedure times [4]. The increased confidence and
predictability offered by Xperius and Onvision will empower more
anesthesiologists to embrace regional anesthesia as a viable and
effective alternative to general anesthesia.
Regional anesthesia or analgesia involves the injection of an
anesthetic in the proximity of a nerve, targeting areas of a
patient’s body that are subject to surgical intervention. Regional
anesthesia can have significant advantages over general anesthesia
for both patients and hospitals. Patients undergoing regional
anesthesia typically benefit from reduced opioid consumption and
fewer side-effects, such as nausea. Moreover, regional anesthesia
may lead to faster post-surgical recovery, allowing patients to
ambulate or leave the hospital sooner, which benefits both patients
and hospitals.
Together, Xperius and Onvision form an integrated point-of-care
solution for supporting current and future needs in regional
anesthesia. They are co-branded and sold via B. Braun’s global
sales network, with Philips providing installation and service.
Xperius is part of Philips’ complete portfolio of point-of-care
ultrasound solutions, which offers clinicians the ability to
confidently diagnose and care for their patients in any work
environment.
[1] Sites et al., 2007[2] Chapman et al., 2006[3] Bartusseck et
al., 2004[4] Kasine et al., 2019
Onvision and Xperius are registered trademarks of B. Braun and
Philips. The Onvision solution is CE marked and available for sale
across the EU and in Chile. It is not currently available for sale
in the United States.
For further information, please contact:
Mark GrovesPhilips Global Press OfficeTel.: +31 631 639
916E-mail: mark.groves@philips.com
Franziska HentschkeB. Braun Melsungen AG Corporate
CommunicationsTel.: +49 5661 711 635E-mail:
franziska.hentschke@bbraun.com
About Royal PhilipsRoyal
Philips (NYSE: PHG, AEX: PHIA) is a leading health technology
company focused on improving people's health and enabling better
outcomes across the health continuum from healthy living and
prevention, to diagnosis, treatment and home care. Philips
leverages advanced technology and deep clinical and consumer
insights to deliver integrated solutions. Headquartered in the
Netherlands, the company is a leader in diagnostic imaging,
image-guided therapy, patient monitoring and health informatics, as
well as in consumer health and home care. Philips generated 2018
sales of EUR 18.1 billion and employs approximately 77,000
employees with sales and services in more than 100 countries. News
about Philips can be found at www.philips.com/newscenter.
About B. BraunB. Braun is one of the world's
leading manufacturers of medical devices and pharmaceutical
products and services. With 64,000 employees in 64 countries, B.
Braun develops high quality product systems and services for users
around the world. In 2018, the Group generated sales of €6.9
billion. Every service provided by B. Braun incorporates its entire
expertise and the company's deep understanding of users' needs. In
developing its products, product systems and services, B. Braun
acts like a sparring partner. A companion who promotes developments
through constructive dialog and the motivation to improve things.
With its constantly growing portfolio of effective medical care
solutions, B. Braun makes a substantial contribution towards
protecting and improving people's health.
- Philips B.Braun Onvision probe needle
- Philips B.Braun Onvision Xperius
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Koninklijke Philips NV (EU:PHIA)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024